RecruitingPhase 1NCT04500847

Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD

Sponsor

Butler Hospital

Enrollment

35 participants

Start Date

Dec 17, 2021

Study Type

INTERVENTIONAL

Conditions

Alzheimer Disease, Early Onset Mild Cognitive Impairment Moderate Dementia

Summary

This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer's disease. Study duration for each subject participating in the placebo-controlled research study will be approximately 12 months (up to a 3 months Screening Period, Baseline visit (1 month), 6 months of placebo or emtricitabine dosing, and 1 month follow-up). Participants will have up to 2 months to complete all procedures for the month 6 study visit.

Eligibility

Min Age: 50 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether a class of HIV drugs (nucleoside reverse transcriptase inhibitors, or NRTIs) might slow or prevent Alzheimer's disease. Scientists have found a possible link between inflammation driven by a cellular process these drugs block, and the brain changes seen in Alzheimer's. **You may be eligible if...** - You are between 50 and 85 years old - You have been diagnosed with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease - You are able to read and understand the language in which the study is conducted - You do not have HIV **You may NOT be eligible if...** - You have moderate or severe dementia - You have significant other neurological conditions (such as Parkinson's disease or a prior major stroke) - You have serious kidney, liver, or heart conditions - You are already taking antiretroviral (HIV) medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.